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Introduction
Wilms tumor gene 1 protein (WT1) is a zinc finger transcription factor involved in the embryonic development of multiple organ systems including kidney, with restricted expression in adult tissues [1] [2] [3] [4] . The function of WT1 is complicated and unclear; it regulates a variety of proteins as a transcription factor, some as an activator and some as a repressor 5 . Multiple cancers demonstrate significantly increased expression of WT1, including myelodysplastic syndromes, acute myeloblastic leukemias, acute lymphoblastic leukemias (ALL), chronic myelogenous leukemia (CML) [6] [7] [8] [9] [10] and many solid tumors 11 including mesotheliomas 12 , ovarian cancer 13 , and various gastrointestinal 14, 15 and central nervous system (CNS) tumors 16 . Over-expression of WT1
has also been demonstrated in the CD34+ stem cells of patients with CML 6 making it an attractive therapeutic target for eradication of this disease.
As an intracellular transcription factor, WT1 currently cannot be inhibited by small molecule drugs or directly targeted by antibody therapies. However, after processing within the For personal use only. on July 15, 2017 . by guest www.bloodjournal.org From cell, peptides from WT1 protein are presented on the cell surface in the context of human leukocyte antigen (HLA) class I molecules. Previous work creating WT1 vaccines to stimulate human cytotoxic T-cells has identified key immunogenic peptide sequences of WT1 presented by HLA 17 ; a number of new epitopes were recently discovered 18 . The widespread expression of this gene product in tumors, its involvement in oncogenesis, and its suppression in normal cells after birth 19 make this a useful tumor marker and an ideal antigen target for cancer therapy 20 .
We have developed an antibody, ESKM, directed against the 9 amino acid peptide RMFPNAPYL (RMF), expressed in the context of HLA-A*02:01 21, 22 ESKM is a T-cell receptor mimic (TCRm) monoclonal human IgG1 in which the Fc portion has been modified by alternative glycosylation that results in stronger binding to effector cell activating Fcγ receptors and increased antibody-dependent cell cytotoxicity (ADCC) 23 . While T-cell based therapies have been attempted against WT1 expressing cancers, monoclonal TCRm antibodies have several advantages over vaccines, TCR constructs, and adaptive T-cells: ESKM can be produced and administered easily; it has greater potency, more predictable and simpler pharmacokinetics, and high efficacy. While several TCRm antibodies have been developed for other antigens 24 , none have entered human trials.
The current standard of care for chronic phase CML is treatment with tyrosine kinase inhibitors (TKIs), but this therapy is not curative, is extremely expensive and may be required life-long 25 . Variable compliance with long-term therapy, with approximately one third of patients stopping TKI's altogether, and the development of mutations that provide resistance to TKIs, frequently results in treatment failure, which sometimes leads to accelerated phase or blast crisis 26, 27 . Long-term use of TKIs used to suppress leukemia leads to a myriad of side effects, including pleural edema, effusions, pulmonary hypertension, sepsis, gastrointestinal problems and lethal cardiovascular events 28, 29 . Furthermore, outside of stem cell transplantation (SCT), there is no effective therapy of CML in blast crisis or Philadelphia chromosome positive (Ph+) ALL 30 ; treatment with TKI's results in brief responses only. The presence of WT1 expression in CML and its progenitors allows us to test for the first time a curative strategy for this disease, by use of ESKM alone or in conjunction with TKIs. In this study, we found ESKM alone was a more effective therapy than TKI's in murine models of human Ph+ ALL. Importantly, the efficacy of the antibody was not affected by the presence of the BCR-ABL "gatekeeper" Effector PBMCs were derived from healthy donors by Ficoll density centrifugation, after obtaining informed consent on a Memorial Sloan Kettering IRB-approved protocol. This study was conducted in accordance with the Declaration of Helsinki.
BV173R Synthesis
The BV173R cell line was engineered to harbor the T315I BCR-ABL, utilizing a
Clonetech pMSCV Puro vector with the T315I BCR-ABL gene, a kind gift from Charles Sawyers 31 . BV173-luc-gfp cells were transduced with the retroviral vector, selected and expanded in media with puromycin. The presence of the resistant T315I mutation was confirmed by PCR for the plasmid, as well as ABL sequencing of cDNA and genomic DNA in the resultant BV173R cell line. Preliminary drug dosing studies in NSG mice demonstrated the MTD of imatinib to be 50 mg/kg IP daily, with higher dosing resulting in diarrhea and severe toxicity. Dasatinib was also initially tested, with the MTD of 40 mg/kg (0.8 mg/mouse) resulting in no appreciable short-term toxicity. However, longer-term trials of dasatinib resulted in mouse sudden deaths, and the dose was therefore lowered for subsequent experiments to 20 mg/kg and then to 10 mg/kg to eliminate drug-related mortality. For mice receiving ponatinib, the initial published dose of 5 mg/kg showed inadequate leukemic affect without any evident health side effects, and therefore ponatinib doses were increased to 10 mg/kg. At this dose, toxicity was comparable to 50 mg/kg of imatinib, with intermittent diarrhea and poor growth.
Flow Cytometry and RT-PCR
All tyrosine kinase inhibitors, including imatinib, dasatinib and ponatinib, and plerixafor were purchased from Selleckchem or Fisher Scientific. The plerixafor stock solution was made in PBS at 200 µg/ml and stored at room temperature. Mice received 1 mg/kg (20 µg per mouse) daily by IP injection, as utilized in previous studies 33 . No toxicity was noted during therapy.
Prior to use in vivo, stock solutions of TKIs were prepared in DMSO, with the scheduled dose of TKI in 50 µL DMSO per mouse. All TKIs and ESKM treatments were administered intraperitoneally at these schedules: ESKM 100 µg twice weekly 23 and TKIs daily. Male NSG mice, 6-8 weeks old, were purchased from Jackson Labs 32 . Three million leukemic cells (BV173 or BV173R) were injected per mouse by tail vein on day 0. Luciferin/luciferase BLI was then performed on day 6, with therapy commencing immediately after confirmation of equivalent levels of disseminated leukemia by imaging. IVIS 200 and IVIS Spectrum machines were used for BLI. 
CD34+ Cell Transplantation

ESKM Therapy with the second generation TKI, dasatinib
Dasatinib is a second generation TKI with far greater potency than imatinib in humans and in animal models 35 . Using the same mouse model as described above, dasatinib administered To determine whether combination therapy with TKI's and ESKM could be optimized by sequential therapies rather than concurrent treatment, BV173 engrafted mice were treated with dasatinib at a lower dose of 20 mg/kg alone for 18 of planned 21 days. By this point, 4 mice receiving dasatinib died, and the remaining11 mice were randomized to receive further treatment: 6 received ESKM, and 5 received no additional therapy. Four weeks of ESKM therapy did delay relapse ( Figure 2D ), but no mice were cured, and ESKM therapy did not result in complete remission as measured by BLI at the end of therapy ( Figure 2E ). Figure 3C ). The mice treated with combination therapy were followed with BLI scans until Day 58. Mouse #2 died on day 31, likely from dasatinib toxicity, and interestingly, the other four mice all showed focal tumor relapse but not recurrent leukemia ( Figure 3D ). This striking pattern of ALL relapse as discrete tumors ( Figure 3E ) is unusual and was only seen with the combination therapy.
Therapy of T315I Resistant Ph+ Leukemia Therapy
BV173R (TKI pan-resistant T315I mutant) leukemia xenografted NSG mice were initially treated with ESKM, imatinib, dasatinib and concurrent combinations of imatinib plus ESKM and dasatinib plus ESKM. Only 3 weeks of therapy were given, as the leukemia proved resistant to the first and second generation TKIs. In contrast, ESKM retained full and equivalent efficacy against the resistant BV173R leukemia compared to TKI sensitive leukemia BV173 ( Figure 4A ) as quantified by luciferase imaging during treatment. These findings are consistent with in vitro studies indicating that in ADCC assays, ESKM is as active against BV173R as it is against BV173 ( Figure 4B ). Dasatinib provided only modest slowing of leukemic growth with leukemic burden rising five-fold over the same time period. The combination of ESKM and dasatinib showed substantial reduction in leukemia burden, though no mice were cured. As in the prior experiments with BV173 treated with the combination ESKM plus dasatinib, relapse was lymphoid tumors rather than diffuse leukemia ( Figure 4C ). The lack of ESKM efficacy on 
Effects in vitro of ESKM and TKIs against Ph+ ALL
The striking activity of ESKM in combination with the two TKI's led us to ask whether there was a mechanistic interaction of the TKI's on the ability of ESKM to kill target cells through its known cytotoxic mode of action, ADCC. Chromium release ( 51 Cr) assay was used to evaluate ESKM directed human peripheral blood mononuclear cell (PBMC) driven ADCC in vitro against BV173. The addition of ESKM resulted in 21-29% ADCC across multiple experiments, using the effector to target ratio (E:T) of 100:1 ( Figure 5A ). Control IgG1 isotype was not cytotoxic. ADCC was also measured in presence of imatinib and dasatinib. Imatinib had no effect on ADCC at concentrations up to 10 µM ( Figure 5B ), at ten times the peak concentrations of this drug in humans. However, dasatinib showed a profound inhibition on ADCC in repeated experiments, with complete inhibition of PBMC mediated ADCC at concentration of 100 nM ( Figure 5C ), the peak concentration of drug in humans.
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We also examined whether TKIs might affect expression of the WT1/HLA epitope, ESKM binding and hence, efficacy. This issue was interrogated both in vitro and in vivo. BV173 cells were grown in culture with imatinib (1 µM), dasatinib (100 nM) and ponatinib (100 nM), in the approximate peak concentrations achieved in vivo by these drugs. Consistent with previously reported studies 37, 38 , exposure of Ph+ cells to high doses of TKIs resulted in significant downregulation of HLA expression and a mild decrease of WT1 (supplementary Figure 4) .
However, this downregulation of HLA was seen in vitro by culturing cells in the prolonged presence of a constant peak dose of TKIs, conditions that are not physiologic.
To evaluate whether TK1 treatment could also decrease HLA or RMF cell surface expression in vivo and thereby contribute to ESKM resistance, BV173 leukemia was extracted immediately following termination of therapy from the imatinib treated mice BM ( Figure 1B) and from the livers of mice treated with dasatinib 10 mg/kg ( Figure 3C ). Five weeks of therapy in vivo with imatinib alone, ESKM alone, or combination of both drugs, did not alter HLA surface expression on CD19+ cells as measured by flow cytometry (supplementary Figure 5A) . Figure 1C 
A small decrease in ESK median binding was seen in cells treated with imatinib (
Leukemia Escape Mechanisms
BV173 leukemia treated with monotherapy for up to 5 weeks with ESKM monotherapy was noted to overgrow in the BM. To evaluate whether BM stromal cells were protective against TCRm therapy, NSG mice engrafted with BV173 were treated for 4 weeks with a combination of ESKM and the CXCR4 inhibitor plerixafor to inhibit binding of the BV173 cells to the stroma.
Treatment with plerixafor was associated with reproducible but not statistically significant reduction in BV173 growth. A concomitant reduction of tumor growth with plerixafor and ESKM treatment was also observed, but the difference in growth inhibition was not significant (supplementary Figure 6A-B) .
We also evaluated whether alterations in HLA expression or presentation of WT1 peptide as measured by ESK binding could alter sensitivity to ESKM mediated ADCC in the presence or 
Activity of ESKM against normal hematopoietic cells
While the potent therapeutic effects in mice appear promising, cytotoxicity against normal hematopoietic cells is a potential risk. Previously we showed that ESKM does not affect 
Discussion:
Compared to TKIs, ESKM is more potent, has a longer half-life and is not susceptible to tumor escape by gatekeeper mutations. ESKM is also a therapeutically effective antibody in mouse models of other human leukemias and solid tumors 23 . However, as monotherapy, the antibody was unable to achieve cures in these models. In combination, TKIs and ESKM did not exhibit enhanced toxicity, had at least an additive therapeutic effect and resulted in molecular cures of Ph+ ALL in mice. BM relapse of leukemia post treatment may reflect inadequate effector cells rather than loss of antigen, or local stromal cell protection, since RMF/HLA-A*02:01 was still expressed on leukemia cells at the end of therapy and reducing leukemic cell adherence to stromal cells with plerixafor did not significantly increase antileukemic activity.
This hypothesis is further supported by the consistent and efficient leukemic cell clearance in the liver, where there are abundant Kupffer cells for ADCC ( Figure 1B) and not in the BM, which lack many effectors in these NSG mice.
The data support a more generally accepted hypothesis that mAb therapies would likely benefit from a second agent to decrease cancer burden and keep cancer growth rates low, thereby fostering more effective ADCC in vivo at increased E:T ratios. Thus, patients with CML in remission on TKIs may be ideal candidates for ESKM treatment, since they have minimal residual leukemic burden and slow cancer growth. The main mechanism of escape of ALL for ESKM monotherapy seemed to be inadequate effector function. Surprisingly, the combination therapy with dasatinib or ponatinib resulted in lymphoid tumor relapse, which is exceedingly rare in CML in humans. We speculate that a lack of effector cells infiltrating the leukemic tumor or the reduced ESKM penetration into the lymphoid tumors may account for this observation.
An important advantage to TCRm antibody therapy was its efficacy against pan-resistant Ph+ leukemias. First and second generation TKI's are not effective against leukemias that carry the BCR-ABL T315I resistance mutation. Such mutations occur in 12-15% of screened patients with CML and are a source of relapse and failure of treatment 40, 41 . While a third generation TKI, ponatinib, is effective in the presence of this mutation, its use is currently restricted because of severe vascular toxicity. Therefore, there is an urgent need for alternative therapies in patients with these mutations. ESKM works through an entirely different mechanism than the TKI's, and our experiments demonstrated equal efficacy of the TCRm mediated ADCC against both TKI sensitive BV173 and its resistant mutant BV173R in vitro and in vivo. Combining ESKM with another TKI could result in faster remissions and possible cure, which may allow a shorter course of these expensive, potentially toxic and non-curative drugs.
While these data strongly support the effectiveness of combining TKIs with ESKM, there are limitations. The patients must be HLA-A*02+, and have leukemias expressing WT1.
Leukemias with reduced HLA-A*02 expression may be resistant to ESKM. Additionally, low Normal NSG mice did not stain for hCD45 (not shown).
For personal use only. on July 15, 2017 
